CompletedPhase 2NCT00027716
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma
Studying Embryonal rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Robert Maki, MD, PhD, MDPhDMemorial Sloan Kettering Cancer Center
- Intervention
- bortezomib(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2001 – 2004
Study locations (6)
- University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora, Colorado, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- University of Chicago Cancer Research Center, New York, New York, United States
- Albert Einstein College of Medicine, The Bronx, New York, United States
- Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00027716 on ClinicalTrials.govOther trials for Embryonal rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06541262Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsMilton S. Hershey Medical Center
- RECRUITINGPHASE1NCT04337177Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid TumorsValent Technologies, LLC